Breaking News

Ligand, Gilead in OmniAb Platform Pact

Gilead will use the OmniRat, OmniMouse and OmniFlic platforms to discover mono- and bispecific antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has entered into a worldwide license agreement with Gilead Sciences, under which Gilead will use the OmniRat, OmniMouse and OmniFlicplatforms to discover fully human mono- and bispecific antibodies for the treatment of various diseases. Ligand is eligible to receive platform access payments, milestones and royalties for each product incorporating an OmniAb antibody. Gilead will be responsible for all costs related to the programs.   “Having access to the OmniAb plat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters